Prognosis
Demand Surging for Wegovy Weight Loss Obesity Drug, Novo Nordisk Says
This article is for subscribers only.
Danish drugmaker Novo Nordisk A/S doubled its 2025 sales target for obesity treatments to 25 billion kroner ($3.7 billion) as it boosts production of Wegovy, its newest weight-loss medication, to keep up with demand.
“It’s clear that there is a large unmet medical need within obesity,” Camilla Sylvest, executive vice president of commercial strategy and corporate affairs, said in a presentation to investors Thursday.